Skip to content
Twitter Facebook-f Youtube Instagram Linkedin
NETs Info
Donate
Close Menu
  • Who We Are
    • About Us
    • Our People
    • Our Board
    • Our Ambassadors
    • Consumer Advisory Group
    • International Advisory Panel
    • Governance & Policy
  • Neuroendocrine Cancers
    • What are Neuroendocrine Cancers?
    • Patient Resources
    • Pheos and Paras
    • NET Library
  • I Am a Patient
    • Patient Support
    • Patient Resources
    • NET Nurse
    • Patient Stories
    • Australian NET Specialists
    • Current Clinical Trials
  • I am a HCP
    • Professional Learning
    • HCP – Patient Referral to NET Nurse
    • Current Clinical Trials
    • NET Library
    • HCP Newsletter & Signup
    • Australian NET Specialists
    • Request an In-Service
    • PLANET Registry
    • Order booklets and other resources
  • Get Involved
    • NET Cancer Day 2022
    • Advocate for us
    • Share your story
    • Donate
    • Fundraise
    • In Memoriam
    • Corporate Partners
    • Gifts & Wills
    • Workplace Giving
    • Volunteer
  • What’s On
    • News
    • Newsletter & Signup
    • INCA Newsletter archive
    • Events
  • Shop
  • Contact Us
Donate
  • Who We Are
    • About Us
    • Our People
    • Our Board
    • Our Ambassadors
    • Consumer Advisory Group
    • International Advisory Panel
    • Governance & Policy
  • Neuroendocrine Cancers
    • What are Neuroendocrine Cancers?
    • Patient Resources
    • Pheos and Paras
    • NET Library
  • I Am a Patient
    • Patient Support
    • Patient Resources
    • NET Nurse
    • Patient Stories
    • Australian NET Specialists
    • Current Clinical Trials
  • I am a HCP
    • Professional Learning
    • HCP – Patient Referral to NET Nurse
    • Current Clinical Trials
    • NET Library
    • HCP Newsletter & Signup
    • Australian NET Specialists
    • Request an In-Service
    • PLANET Registry
    • Order booklets and other resources
  • Get Involved
    • NET Cancer Day 2022
    • Advocate for us
    • Share your story
    • Donate
    • Fundraise
    • In Memoriam
    • Corporate Partners
    • Gifts & Wills
    • Workplace Giving
    • Volunteer
  • What’s On
    • News
    • Newsletter & Signup
    • INCA Newsletter archive
    • Events
  • Shop
  • Contact Us

Home » General » Pharmaceutical Benefits Advisory Committee to Consider Everolimus for Metastatic Pancreatic Neuroendocrine Cancer

Pharmaceutical Benefits Advisory Committee to Consider Everolimus for Metastatic Pancreatic Neuroendocrine Cancer

  • January 22, 2014
When the Pharmaceutical Benefits Advisory Committee (PBAC) meets in March, everolimus (Afinitor), a mTOR inhibitor is being resubmitted for the treatment of metastatic or unresectable well differentiated pancreatic neuroendocrine (pNET) cancer.

Everolimus suppressed/slowed tumour growth and reduced the risk of cancer progression for 11 months (median) compared with 4 months on placebo (more than double). Improvement in progression free survival whilst taking everolimus was seen in all patient groups.

This is significant clinical result, and our Australian NET Specialists need to be able to prescribe and treat our pNET patients with everolimus to ensure that they are getting the best possible care. However, without PBS listing this drug will cost our patients thousands of dollars per month to access it. Therefore it is imperative that we let the Committee know that we need everolimus listed.

The PBAC is seeking consumer submissions for this listing and the Unicorn Foundation strongly encourages our all our NET patients to complete the online form and help us get this drug listed on the Pharmaceutical Benefits Scheme, allowing current and future pNET patients equitable access to this potent drug.

For guidance in completing the submission please download the PBAC consumer notes.

Share this post

Subscribe to our eNews

Stay up to date on news and events, clinical trials and new research on neuroendocrine cancers.

Recent posts

World Cancer Day 2023

January 10, 2023

Support Groups Christmas Gatherings

December 20, 2022

NeuroEndocrine Cancer Australia & Norman Family Trust Partnership

December 14, 2022

NeuroEndocrine Cancer Australia partners with Gathered Here to provide the NET community with free online Wills

December 14, 2022
Categories
  • Advocacy
  • Awareness
  • Community Events
  • Education
  • Events
  • Fundraising
  • General
  • In The Media
  • News
  • Research
  • Unicorn Events
PrevPreviousInagural APNETS Conference
NextCDA Stakeholder ForumNext

Related Posts

NECA Finalist as NGO of the Year in Prime Awards

We’re thrilled to be announced as one of the finalists in the NGO of The Year category in the 2022 PRIME Awards Australia. The Prime

COVID-19 Information and Resources

A note from our CEO on COVID-19: To our wonderful NET community we stand with you and alongside you as we get through this unprecedented

Expression-of-Interest for consumer participation on Grant Review Committees for the 2022 Priority-driven Collaborative Cancer Research Scheme

Cancer Australia’s Priority-driven Collaborative Cancer Research Scheme (PdCCRS) is an innovative, competitive, annual cancer research projects grant funding scheme. The PdCCRS is conducted by Cancer

32 neuroendocrine tumour presentations at ASCO annual scientific conference

The ASCO Annual Conference was held virtually this year from 29 – 31 May 2020 with 32 Neuroendocrine presentations from this meeting delivered orally, by

View All

Make a difference

How much do you wish to donate?
$50
$100
$250
$500
$1000
Other
NeuroEndocrine Cancer Australia logo white
Twitter Facebook-f Youtube Instagram Linkedin

All donations are tax deductible.
Registered Charity CFN 202607

Who We Are

  • About Us
  • Our People
  • Our Ambassadors
  • Consumer Advisory Group
  • International Advisory Panel
  • Governance & Policies
  • About Us
  • Our People
  • Our Ambassadors
  • Consumer Advisory Group
  • International Advisory Panel
  • Governance & Policies

Neuroendocrine Cancers

  • What are Neuroendocrine Cancers?​
  • Pheos and Paras
  • NET Library
  • What are Neuroendocrine Cancers?​
  • Pheos and Paras
  • NET Library

For Patients

  • Patient resources
  • NET Nurse
  • Patient Stories
  • Australian NET Specialists
  • Current Open Clinical Trials
  • Patient resources
  • NET Nurse
  • Patient Stories
  • Australian NET Specialists
  • Current Open Clinical Trials

Get Involved

  • Shop
  • Donate
  • Volunteer
  • Current Fundraising Campaigns
  • Fundraise
  • Shop
  • Donate
  • Volunteer
  • Current Fundraising Campaigns
  • Fundraise

© 2020 NeuroEndocrine Cancer Australia

  • Website by Five Creative